Sirona Biochem Corp Stock Fundamentals
| SRBCF Stock | USD 0.05 0 9.89% |
Sirona Biochem Corp fundamentals help investors to digest information that contributes to Sirona Biochem's financial success or failures. It also enables traders to predict the movement of Sirona Pink Sheet. The fundamental analysis module provides a way to measure Sirona Biochem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sirona Biochem pink sheet.
Sirona |
Sirona Biochem Corp Company Return On Equity Analysis
Sirona Biochem's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sirona Biochem Return On Equity | -35.56 |
Most of Sirona Biochem's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sirona Biochem Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sirona Biochem Corp has a Return On Equity of -35.557. This is 48.34% higher than that of the Biotechnology sector and 2.48% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Sirona Biochem Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sirona Biochem's current stock value. Our valuation model uses many indicators to compare Sirona Biochem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sirona Biochem competition to find correlations between indicators driving Sirona Biochem's intrinsic value. More Info.Sirona Biochem Corp is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sirona Biochem's earnings, one of the primary drivers of an investment's value.Sirona Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sirona Biochem's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sirona Biochem could also be used in its relative valuation, which is a method of valuing Sirona Biochem by comparing valuation metrics of similar companies.Sirona Biochem is currently under evaluation in return on equity category among its peers.
Sirona Fundamentals
| Return On Equity | -35.56 | |||
| Return On Asset | -1.35 | |||
| Operating Margin | (4.92) % | |||
| Current Valuation | 24.5 M | |||
| Shares Outstanding | 251.73 M | |||
| Shares Owned By Insiders | 10.43 % | |||
| Price To Earning | (7.33) X | |||
| Price To Book | 36.93 X | |||
| Price To Sales | 36.46 X | |||
| Revenue | 268.02 K | |||
| Gross Profit | 199.25 K | |||
| EBITDA | (2.3 M) | |||
| Net Income | (2.31 M) | |||
| Cash And Equivalents | 1.13 M | |||
| Total Debt | 468.77 K | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 2.60 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.16 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 12 | |||
| Beta | -0.36 | |||
| Market Capitalization | 20.74 M | |||
| Total Asset | 1.29 M | |||
| Retained Earnings | (12.03 M) | |||
| Working Capital | 692 K | |||
| Current Asset | 1.49 M | |||
| Current Liabilities | 801 K | |||
| Z Score | 10.5 | |||
| Net Asset | 1.29 M |
About Sirona Biochem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sirona Biochem Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sirona Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sirona Biochem Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. The company was incorporated in 2006 and is headquartered in Vancouver, Canada. Sirona Biochem is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Sirona Pink Sheet
Sirona Biochem financial ratios help investors to determine whether Sirona Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sirona with respect to the benefits of owning Sirona Biochem security.